In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Human Longevity closes $220mm Series B round

Executive Summary

Human Longevity Inc. (HLI) raised $220mm through its Series B round from investors including Illumina, Celgene, GE Ventures, and buyers from the firm's Series A round (which closed at $80mm late last year). The company, which is creating a database of whole genome, phenotype, and clinical data for therapeutic and diagnostic use, will put the Series B money towards expansion of its products, including supporting HLI's first Health Nucleus division, a genomic enhanced health center, and growing HLI's Knowledgebase of genomic and phenotypic data.
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Services
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies